Calquence is designed to treat lymphoma but may reduce the inflammation caused by the coronavirus, which can trigger an extreme immune reaction called a cytokine storm that can be fatal.
The drug will be tested on hospitalized COVID-19 patients in a large randomized trial, with the first participants being recruited from the U.S. and Europe.
The drugmaker is hoping the drug could reduce the number of patients needed to be put on ventilators.
Read the full news release here.
More articles on pharmacy:
Johnson & Johnson warns of temporary Tylenol shortage
A breakdown of 6 of the most promising COVID-19 treatments
Employees test positive for COVID-19 at mail-order VA pharmacy in South Carolina
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.